Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Jonathan I. Silverberg(George Washington University), Alan Clucas(Fondation Sophia Antipolis), Lisa Lindsey(Galderma (United States)), Christophe Piketty(Galderma (Switzerland)), Andrew Alexis(Icahn School of Medicine at Mount Sinai), Dédée F. Murrell(Sutherland Hospital), Yves Poulin(ENT and Allergy), Andreas Wollenberg(University Hospital Augsburg), Jean‐David Bouaziz(Université Paris Cité), Faiz Ahmad(Galderma (United States)), Grażyna Pulka(Jagiellonian University), Andreas Pinter(Goethe University Frankfurt)
Cited by 268
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification
|Journal of the American Academy of Dermatology|2014|933
The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB
|Journal of the American Academy of Dermatology|2008|933
Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility
|British Journal of Dermatology|2020|778